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Choice underpins everything we do as critical care clinicians.
We choose whether to treat, when to treat and how to treat
from an ever-increasing selection of alternatives, and whether
to afford the costs associated with the decisions we have
made. Some recent articles have looked at how one chooses
to ventilate patients (noninvasively or not), how to deal with
and avoid ventilator-acquired pneumonia, and which
regimens of antibiotics to use and how it affects outcome. It
is these articles on which we shall focus.
Choose well
Choosing the antibiotic to use in early sepsis is influenced by
many things: likely causative organisms for the source found,
if any; local variations of pathogens; and known patterns of
resistance. Logically, then, targeting sepsis with the correct
initial antibiotic choice should influence overall patient
outcome. But does it?
Garnacho-Montero and colleagues looked at how adequate
empirical antibiotic choice affected outcome and the mortality
rate in 400 patients on admission to the intensive care unit
(ICU) [1]. Adequate meant at least one effective drug (two
drugs for Pseudomonas infection), as judged by antimicrobial
susceptibility, included in the empirical antibiotic treatment.
Garnacho-Montero and colleagues found that inhospital
mortality was eight times more probable in patients receiving
inadequate antimicrobial therapy in the first 24 hours, and
that adequate therapy reduced mortality by almost two-thirds
in surgical sepsis (where surgery is a necessary part of
infection treatment). Antibiotic therapy in the preceding
month and, not surprisingly, fungal infection meant empirical
therapy was likely to be inadequate.
Early adequate antibiotics do seem to matter, but not as
much in ventilator-acquired pneumonia (VAP) as expected
when considered by Leroy and colleagues [2]. Although
adequate antibiotics were associated with a significantly
lower mortality rate, they were not an independent prognostic
factor. However, thrombocytopaenia and extensive lung
radiographic appearances (as these authors have stated
previously [3]) were an independent prognostic factor.
Still with the antibiotic theme, many units are adopting
rotating schedules of antibiotics in an effort to combat
multiresistance. Raymond and colleagues have already
suggested that this regimen may improve mortality on the
ICU [4], but what happens when patients are discharged to
the ward? It seems that if the regimen is carried over, then so
are the benefits — even to patients on the ward admitted from
elsewhere [5]. Interestingly, the length of stay on the ward
seemed to increase with the rotating regimen but, as
Raymond and colleagues point out, this may be because it
allows sicker ICU patients to survive longer; and they then
require a protracted ward stay. In any case, their results
suggest rotation may be the way forward in our war against
the bacteria.
Treat well
VAP is regrettably the most common nosocomial infection on
the ICU. Its implications for patient care are manifold. Does
giving a patient a percutaneous tracheostomy (PCT)
predispose them to VAP? If so, how does it affect outcome?
Rello and colleagues studied this association in almost 100
patients [6]. They found in their cohort that at least
performing PCT increased the risk of VAP. This in turn
lengthened the duration of ventilation and of the ICU stay, but
did not seem to increase mortality. Neither did organisms
colonising pre-PCT predict the pneumonic organism.
However, patients receiving PCT are slower to wean from
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ventilation (and therefore to undergo PCT) and so are
predisposed to VAP by definition. The only real way to show
that these slow weaners are worse off with a PCT would be
to randomise them to PCT or to continued oral intubation.
Would continued oral intubation have more morbidity and
VAP because of the continued need for sedation? Perhaps
this is the trial we need. But then again, prolonged oral
intubation has problems all of its own.
So how can we prevent VAP? Many strategies have been
tried but, mortality and morbidity aside, is their
implementation cost-effective in terms of the increased
treatment costs associated with VAP? van Nieuwenhoven
and colleagues set out to find the cost of oral
decontamination [7], having previously shown it to reduce the
incidence of VAP [8], and to show that there are benefits, at
least in terms of costs incurred on the ICU and those
associated with VAP. Assuming similar costs elsewhere,
notwithstanding the benefits of oral decontamination,
perhaps this is a strategy we should all be adopting.
Get well
There is definitely growing interest in noninvasive ventilation
(NIV); more so where inspiratory effort is supported by
increased positive pressure, pressure support. The debate
continues as to whether NIV is truly effective, under what
circumstances, and which patients should receive it.
Thankfully more studies are being powered to answer these
questions.
Nava and colleagues looked at NIV with pressure support in a
pre-ICU setting [9]. Their end points were the reduction in
mortality and the need for intubation using this modality in
patients with cardiogenic pulmonary oedema. Outcomes were
the same overall but, importantly, NIV did not increase the risk
of myocardial infarction. Specifically, however, hypercapnoeic
patients improved faster and avoided the need for intubation
when compared with those patients receiving only medical
therapy and oxygen. Of course, in terms of feasibility, these
patients will need at least level 1 care.
Ferrer and colleagues considered NIV in 105 acutely hypoxic
patients [10], excluding hypercapnoeic patients. They also
showed decreased necessity for intubation, improved survival
on the ICU and beyond, and reduced incidence of
nosocomial pneumonia (with shock). Ferrer and colleagues
also specifically show reduced intubation rates in those
patients with pneumonia and no underlying predisposition to
respiratory failure, perhaps for the first time.
Choose best?
Finally, which is the expert choice, and on what basis? Perrin
and colleagues surveyed UK clinicians (general and
respiratory physicians, and intensivists) to investigate their
clinical decision-making and criteria for initiation of ventilation
in patients with respiratory failure due to exacerbation of
chronic obstructive pulmonary disease [11]. All three groups
selected similar factors for withholding or initiating ventilation,
but these were not necessarily recognised predictors of
outcome. There were, however, wide variations between
individuals. Guidelines are needed.
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